Consensus guideline for the diagnosis and management of mannose phosphate isomerase‐congenital disorder of glycosylation
- 21 April 2020
- journal article
- review article
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 43 (4), 671-693
- https://doi.org/10.1002/jimd.12241
Abstract
Mannose phosphate isomerase deficiency (MPI‐CDG) is a rare subtype of congenital disorders of protein N‐glycosylation. It is characterized by deficiency of mannose phosphate isomerase (MPI) caused by pathogenic variants in MPI gene. The manifestation of MPI‐CDG is different from other CDGs as the patients suffer dominantly from gastrointestinal and hepatic involvement whereas they usually do not present intellectual disability or neurological impairment. It is also one of the few treatable subtypes of CDGs with proven effect of oral mannose. This article covers a complex review of the literature and recommendations for the management of MPI‐CDG with an emphasis on the clinical aspect of the disease. A team of international experts elaborated summaries and recommendations for diagnostics, differential diagnosis, management and treatment of each system/organ involvement based on evidence‐based data and experts’ opinions. Those guidelines also reveal more questions about MPI‐CDG which need to be further studied.Keywords
Funding Information
- National Institutes of Health (1 U54 NS115198‐01 PI)
- Ministerstvo Zdravotnictví Ceské Republiky (MZ CR AZV 16‐31932A)
This publication has 94 references indexed in Scilit:
- Identification of Intercellular Cell Adhesion Molecule 1 (ICAM-1) as a Hypoglycosylation Marker in Congenital Disorders of Glycosylation CellsOnline Journal of Public Health Informatics, 2012
- Antithrombotic Therapy in Neonates and Children: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice GuidelinesSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2012
- A zebrafish model of congenital disorders of glycosylation with phosphomannose isomerase deficiency reveals an early opportunity for corrective mannose supplementationDisease Models & Mechanisms, 2012
- Expanding the Spectrum of PMM2-CDG PhenotypeJIMD Reports, 2011
- Seizures and stupor during intravenous mannose therapy in a patient with CDG syndrome type 1b (MPI‐CDG)Journal of Inherited Metabolic Disease, 2010
- The Liver in Congenital Disorders of Glycosylation: Ultrastructural FeaturesUltrastructural Pathology, 2007
- Heparan Sulfate Plays a Central Role in a Dynamic in Vitro Model of Protein-losing EnteropathyOnline Journal of Public Health Informatics, 2006
- A Novel Disorder of N-Glycosylation Due to Phosphomannose Isomerase DeficiencyBiochemical and Biophysical Research Communications, 1998
- Secretory diarrhea with protein-losing enteropathy, enterocolitis cystica superficialis, intestinal lymphangiectasia, and congenital hepatic fibrosis: A new syndromeThe Journal of Pediatrics, 1986
- The Honeybee Syndrome — Implications of the Teratogenicity of Mannose in Rat-Embryo CultureThe New England Journal of Medicine, 1984